 Methods: Eligible patients will be treated with 2 weeks of single agent lenvatinib, followed by 12 weeks of lenvatinib letrozole. Blood and tumor samples will be obtained from the patient serially to study tumor and host factors that may influence drug efficacy and toxicity. 